Currently, an active clinical trial (NCT02367859) with the combinatory use of dabrafenib (a BRAF inhibitor) and trametinib (MEK inhibitor) for treatment of AM is undergoing, but the clinical outcomes remain unknown. The gene discussed is MAP2K7; the disease is acute myeloblastic leukemia with maturation.